Striking a Balance: Understanding Pain Management & Opioids- A case-based curriculum

Speaker: Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

Learning Outcome: During this 2-hour course advanced practice nurses will increase their knowledge and skills regarding the latest evidence for understanding pain management and opioids and will be able to apply that information to their practices to improve their patient outcomes. This newly updated course is designed to meet the FDA’s Opioid Analgesic REMS.

The course curriculum is fully compliant with the FDA’s September 2018 FDA Blueprint for Opioid Analgesic REMS Education and the 2022 Centers for Disease Control and Prevention (CDC) Clinical Practice Guideline for Prescribing Opioids for Pain. This session also meets many states’ requirements for controlled substances CE.

CO*RE Case-Based Curriculum: Our case-based session delivers a real-world educational experience through a series of cases and supporting content mapped to segments of the FDA Blueprint. This allows faculty to teach the application of concepts, fostering an engaging approach to pain management education.


The curriculum was developed by the Collaborative for REMS Education (CO*RE) and is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies (RPC).

This course meets the criteria outlined by Substance Abuse and Mental Health Services Administration (SAMHSA) to count toward DEA required training.  The  Access and Training Expansion (MATE) Act requires new or renewing Drug Enforcement Agency (DEA) registrants, as of June 27, 2023, to have completed a total of at least eight hours of training on opioid or other substance use disorders.

Contact Information: Presented by Nurse Practitioner Healthcare Foundation,  a member of the Collaborative on REMS Education (CO*RE), ten interdisciplinary organizations working together to improve pain management and prevent adverse outcomes, including AAFP, AANP, AAPA, AAHPM, AOA, ASAM, CAFP, IPMA, NPHF & AAOS.  For more information, please contact NPHF or visit


Lauch Date: February 9, 2024    Expiration Date: October 9, 2024

CE for Nurses/Nurse Practitioners:

Here is the link to REQUIRED evaluation and posttest:

Completion is REQUIRED of the activity, evaluation and post-test below to receive your ANCC Certificate of Completion.  It will take you less than 10 minutes to complete.  You will receive your certificate via email within 10 days. We will not share your personal information. Thank you! 


Accreditation Statement: The Nurse Practitioner Healthcare Foundation (NPHF) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria.  This learning activity is presented in partnership with the CO*RE Collaborative.

Criteria for Awarding Contact Hours: This course provides 2.00 contact hours including 2.00 pharmacology hours. Criteria for awarding the contact hour includes completion of the course, evaluation and post-test.

Accredited Provider Disclosure: As a provider dedicated to independent education and accredited by the ANCC, NPHF must ensure balance, independence, objectivity, and scientific rigor in all it's educational activities. All individuals with the ability to influence the content of this educational activity reported the following:  none of the faculty advisors, reviewers or planners for this educational activity have relevant financial relationships with ineligible companies to disclose.

Wendy Wright,  DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, faculty for this educational event, is on the speaker bureau is a consultant for GSK.  Relevant financial relationships have been mitigated.

Commercial Support: This educational activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies (RPC).  Please see for a listing of the member companies.  This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration (FDA).